Company / Cash & Equivalents
iBio, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.6M
FY2025
5-year range
$4.3M / $55.1M
FY2021-FY2025
Trend
+99.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $4M to $9M over the past 2 years.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +14.2%.
Improved from $4M to $9M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -27.7%
- 5-Year CAGR
- +14.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +14.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 99.5% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.36 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.6M | +99.5% |
| FY2024 | $4.3M | +0.0% |
| FY2023 | $4.3M | -81.0% |
| FY2022 | $22.7M | -58.9% |
| FY2021 | $55.1M | +1146.6% |
| FY2020 | $4.4M | -45.3% |
| FY2019 | $8.1M | -64.9% |
| FY2018 | $23.0M | +0.0% |
| FY2017 | $23.0M | +142.4% |
| FY2016 | $9.5M | +164.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026